Communiqués Ocular Therapeutix, Inc.

Actions

OCUL

US67576A1007

Produits pharmaceutiques

Temps réel estimé Cboe BZX 21:19:32 14/08/2026			Varia. 5j.	Varia. 1 janv.
9,890 ^USD	-2,08%		+7,67%	-18,49%

04/08	Ocular Therapeutix : le calendrier de soumission de la NDA pour l'Axpaxli dans la DMLA humide reste inchangé, selon RBC	MT
03/08	Ocular Therapeutix, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI

Communiqués

13/08	Ocular Therapeutix : trade; Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	PU
07/08	Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
03/08	Ocular Therapeutix: Q2 Earnings Snapshot	AQ
03/08	Ocular Therapeutix™ Reports Second Quarter 2026 Financial Results and Business Highlights	AQ
09/07	Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
01/07	Ocular Therapeutix™ to Participate in July Scientific and Investor Conferences	AQ
22/06	Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
17/06	Ocular Therapeutix™ Investor Day to Highlight U.S. FDA Alignment on AXPAXLI™ NDA with Submission Planned for Fourth Quarter 2026	AQ
08/06	Ocular Therapeutix Reports Inducement Grants under Nasdaq Listing Rule 5635(4)	AQ
05/06	Ocular Therapeutix to Participate in Clinical Trials at the Summit 2026	AQ
05/06	Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
04/06	Ocular Therapeutix™ to Participate in Clinical Trials at the Summit 2026	AQ
02/06	Ocular Therapeutix™ to Host Investor Day on June 17, 2026	AQ
08/05	Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
05/05	Ocular Therapeutix: Q1 Earnings Snapshot	AQ
05/05	Ocular Therapeutix™ Reports First Quarter 2026 Financial Results and Business Highlights	AQ
30/04	Ocular Therapeutix Announces First Patient Enrolled in SOL-X Long-Term Extension Trial for AXPAXLI in Wet AMD	AQ
29/04	Ocular Therapeutix™ Announces First Patient Enrolled in SOL-X Long-Term Extension Trial for AXPAXLI™ in Wet AMD	AQ
28/04	Ocular Therapeutix™ to Report First Quarter 2026 Financial Results on May 5, 2026	AQ
27/04	Ocular Therapeutix™ to Participate in May Scientific and Investor Conferences	AQ
22/04	Ocular Therapeutix™ to Host Investor Day on June 17, 2026	AQ
15/04	Ocular Therapeutix Reports Inducement Grants under Nasdaq Listing Rule 5635(4)	AQ
14/04	Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
13/04	Ocular Therapeutix™ Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI™ in Wet AMD	AQ
01/04	Ocular Therapeutix™ to Present Additional SOL-1 Data and Analyses at Upcoming Scientific Conferences in April	AQ